Keep an eye on the top gainers and losers in Monday's session. Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Why Did RARE Stock Plunge Over 41% Today? Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.
Traders are paying attention to the gapping stocks in Monday's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment.
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.
Let's take a look at the stocks that are in motion in today's session. Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
